Faculty of Pharmacy Newsletter:@0.147970:0.965677:0.401979:0.965677:0.401979:0.947594:0.147970:0.947594:0.011291:0.009239:0.008205:0.010274:0.005137:0.006153:0.009239:0.004620:0.009239:0.006153:0.004620:0.011291:0.010274:0.009239:0.008205:0.015393:0.009239:0.008205:0.009239:0.004620:0.013342:0.008205:0.013342:0.007188:0.005137:0.008205:0.006153:0.006153:0.008205:0.008205
42:@0.104524:0.971012:0.136879:0.971012:0.136879:0.940075:0.104524:0.940075:0.015815:0.016540
Chapter VI:@0.103809:0.063855:0.218582:0.063855:0.218582:0.040840:0.103809:0.040840:0.016980:0.013076:0.011759:0.013076:0.007832:0.010442:0.010021:0.005456:0.016980:0.009149
1:@0.104762:0.115984:0.122401:0.115984:0.122401:0.081462:0.104762:0.081462:0.017639
st:@0.122401:0.104266:0.136407:0.104266:0.136407:0.084139:0.122401:0.084139:0.007003:0.007003
  publication  affiliated  with  Faculty  of  Pharmacy :@0.136400:0.115984:0.904386:0.115984:0.904386:0.081462:0.136400:0.081462:0.008819:0.006854:0.019614:0.019614:0.019614:0.009807:0.009807:0.015663:0.017639:0.011747:0.009807:0.017639:0.019614:0.008819:0.006854:0.017639:0.009384:0.009384:0.009384:0.009807:0.009807:0.017639:0.011747:0.015663:0.019614:0.008819:0.006854:0.025471:0.009807:0.011747:0.019614:0.008819:0.006858:0.021555:0.017639:0.015663:0.019614:0.009807:0.011747:0.017639:0.008819:0.006847:0.017639:0.011747:0.008819:0.006854:0.021555:0.019614:0.017639:0.015663:0.029386:0.017639:0.015663:0.017639:0.008819
 :@0.895556:0.115984:0.904375:0.115984:0.904375:0.081462:0.895556:0.081462:0.008819
Mansoura National  University:@0.104762:0.142116:0.588543:0.142116:0.588543:0.107593:0.104762:0.107593:0.033302:0.017639:0.019614:0.013723:0.017639:0.019614:0.015663:0.017639:0.021414:0.025471:0.017639:0.011747:0.009807:0.017639:0.019614:0.017639:0.009807:0.008819:0.012577:0.025471:0.019614:0.009807:0.017639:0.015663:0.015663:0.013723:0.009807:0.011747:0.017639
International Immunopharmacology:@0.260700:0.185705:0.720259:0.185705:0.720259:0.157077:0.260700:0.157077:0.011763:0.016812:0.008406:0.013426:0.011763:0.016812:0.015119:0.008406:0.008406:0.015119:0.016812:0.015119:0.008406:0.007560:0.011763:0.023525:0.023525:0.016812:0.016812:0.015119:0.015119:0.016812:0.015119:0.011763:0.023525:0.015119:0.013426:0.015119:0.008406:0.015119:0.015119:0.013426
Volume 121, August 2023, 110442:@0.349803:0.207273:0.631148:0.207273:0.631148:0.188188:0.349803:0.188188:0.011212:0.010079:0.005604:0.011208:0.015683:0.008950:0.005040:0.010079:0.010079:0.010079:0.005040:0.004284:0.013446:0.011208:0.010079:0.011208:0.006632:0.006632:0.005040:0.010079:0.010079:0.010079:0.010079:0.005040:0.005040:0.008967:0.010079:0.010079:0.010079:0.010079:0.010079
Celecoxib  abrogates  concanavalin  A-induced :@0.104762:0.237603:0.493150:0.237603:0.493150:0.218404:0.104762:0.218404:0.013446:0.008950:0.005604:0.008950:0.008950:0.010079:0.010079:0.005604:0.010079:0.005040:0.006298:0.008950:0.010079:0.006713:0.010079:0.010079:0.008950:0.005604:0.008950:0.007842:0.005040:0.006308:0.008950:0.010079:0.010079:0.008950:0.008950:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.010079:0.005040:0.005185:0.014555:0.006713:0.005604:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:0.005040
hepatitis in mice: Possible involvement of Nrf2/:@0.104762:0.254708:0.488100:0.254708:0.488100:0.235508:0.104762:0.235508:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.005604:0.005604:0.007842:0.004340:0.005604:0.010079:0.004352:0.015683:0.005604:0.008950:0.008950:0.005604:0.004344:0.011208:0.010079:0.007842:0.007842:0.005604:0.010079:0.005604:0.008950:0.004354:0.005604:0.010079:0.010079:0.010079:0.005604:0.010079:0.008950:0.015683:0.008950:0.010079:0.005604:0.004338:0.010079:0.006713:0.004356:0.014555:0.006713:0.006713:0.010079:0.005604
HO-1,  JNK  signaling  pathways  and  COX-2 :@0.104762:0.271812:0.493128:0.271812:0.493128:0.252613:0.104762:0.252613:0.014555:0.014555:0.006713:0.010079:0.005040:0.005040:0.006350:0.007842:0.014555:0.014555:0.005040:0.006354:0.007842:0.005604:0.010079:0.010079:0.008950:0.005604:0.005604:0.010079:0.010079:0.005040:0.006334:0.010079:0.008950:0.005604:0.010079:0.014555:0.008950:0.010079:0.007842:0.005040:0.006340:0.008950:0.010079:0.010079:0.005040:0.006340:0.013446:0.014555:0.014555:0.006713:0.010079:0.005040
expression:@0.104762:0.288917:0.194791:0.288917:0.194791:0.269717:0.104762:0.269717:0.009374:0.010503:0.010503:0.007136:0.009374:0.008265:0.008265:0.006027:0.010503:0.010079
Aya khaleel , :@0.104762:0.312755:0.216529:0.312755:0.216529:0.293555:0.104762:0.293555:0.012708:0.010079:0.008950:0.005872:0.010079:0.010079:0.008950:0.005604:0.008950:0.008950:0.005604:0.005859:0.005040:0.005040
1:@0.200573:0.306184:0.206450:0.306184:0.206450:0.294991:0.200573:0.294991:0.005876
Ahmed R. El-Sheakh:@0.217364:0.313054:0.401059:0.313054:0.401059:0.293327:0.217364:0.293327:0.014555:0.011208:0.016792:0.008950:0.011208:0.005882:0.014555:0.005040:0.005878:0.013446:0.005604:0.006713:0.011208:0.011208:0.008950:0.010079:0.011208:0.011208
1,2,3:@0.401064:0.306358:0.424569:0.306358:0.424569:0.294858:0.401064:0.294858:0.005876:0.002938:0.005876:0.002938:0.005876
, Ghada :@0.424569:0.312755:0.493137:0.312755:0.493137:0.293555:0.424569:0.293555:0.005040:0.005874:0.014555:0.010079:0.008950:0.010079:0.008950:0.005040
M. Suddek ,*:@0.104762:0.329859:0.215443:0.329859:0.215443:0.310660:0.104762:0.310660:0.017921:0.005040:0.006249:0.011208:0.010079:0.010079:0.010079:0.008950:0.010079:0.005876:0.005040:0.010079
1:@0.194447:0.323288:0.200324:0.323288:0.200324:0.312095:0.194447:0.312095:0.005876
1:@0.104762:0.347127:0.110638:0.347127:0.110638:0.335933:0.104762:0.335933:0.005876
 Department of Pharmacology and Toxicology, :@0.110638:0.353698:0.493136:0.353698:0.493136:0.334498:0.110638:0.334498:0.005013:0.014555:0.008950:0.010079:0.008950:0.006713:0.005604:0.015683:0.008950:0.010079:0.005604:0.004995:0.010079:0.006713:0.005013:0.011208:0.010079:0.008950:0.006713:0.015683:0.008950:0.008950:0.010079:0.005592:0.010079:0.010079:0.010079:0.005011:0.008950:0.010079:0.010079:0.004647:0.010906:0.010079:0.010079:0.005604:0.008950:0.010079:0.005604:0.010079:0.010079:0.008761:0.005040:0.005040
Faculty  of  Pharmacy,  Mansoura  University, :@0.104762:0.370802:0.493136:0.370802:0.493136:0.351602:0.104762:0.351602:0.011208:0.008950:0.008950:0.010079:0.005604:0.005604:0.010079:0.005040:0.008023:0.010079:0.006713:0.005040:0.008033:0.011208:0.010079:0.008950:0.006713:0.015683:0.008950:0.008950:0.008759:0.005040:0.005040:0.008033:0.017921:0.008950:0.010079:0.007842:0.010079:0.010079:0.006713:0.008950:0.005040:0.008033:0.014555:0.010079:0.005604:0.010079:0.008950:0.006713:0.007842:0.005604:0.005604:0.008765:0.005040:0.005040
Mansoura,  Egypt.:@0.104762:0.387906:0.255212:0.387906:0.255212:0.368707:0.104762:0.368707:0.017921:0.008950:0.010079:0.007842:0.010079:0.010079:0.006713:0.008950:0.005040:0.005040:0.006558:0.012317:0.010079:0.010079:0.010079:0.005604:0.005040
2:@0.104762:0.405174:0.110638:0.405174:0.110638:0.393980:0.104762:0.393980:0.005876
 Department of Pharmacology and Toxicology, :@0.110638:0.411745:0.493136:0.411745:0.493136:0.392545:0.110638:0.392545:0.005013:0.014555:0.008950:0.010079:0.008950:0.006713:0.005604:0.015683:0.008950:0.010079:0.005604:0.004995:0.010079:0.006713:0.005013:0.011208:0.010079:0.008950:0.006713:0.015683:0.008950:0.008950:0.010079:0.005592:0.010079:0.010079:0.010079:0.005011:0.008950:0.010079:0.010079:0.004647:0.010906:0.010079:0.010079:0.005604:0.008950:0.010079:0.005604:0.010079:0.010079:0.008761:0.005040:0.005040
Faculty  of  Pharmacy,  Mansoura  National :@0.104762:0.428849:0.493138:0.428849:0.493138:0.409764:0.104762:0.409764:0.013446:0.010079:0.008950:0.011208:0.005604:0.005604:0.008950:0.005040:0.008507:0.010079:0.006713:0.005040:0.008517:0.012317:0.011208:0.010079:0.007842:0.015683:0.010079:0.008950:0.008197:0.005040:0.005040:0.008517:0.017921:0.010079:0.011208:0.007842:0.010079:0.011208:0.007842:0.010079:0.005040:0.008533:0.014555:0.010079:0.005604:0.005604:0.010079:0.011208:0.010079:0.005604:0.005040
University,  Gamasa,  Egypt.:@0.104762:0.445954:0.341780:0.445954:0.341780:0.426868:0.104762:0.426868:0.014555:0.011208:0.005604:0.008950:0.008950:0.007842:0.007842:0.005604:0.005604:0.008197:0.005040:0.005040:0.005491:0.014555:0.010079:0.015683:0.010079:0.007842:0.010079:0.005040:0.005040:0.005495:0.013446:0.010079:0.008950:0.010079:0.005604:0.005040
3:@0.104762:0.463221:0.110638:0.463221:0.110638:0.452027:0.104762:0.452027:0.005876
  Future  Studies  and  Risks  Management’ :@0.110638:0.469792:0.493148:0.469792:0.493148:0.450592:0.110638:0.450592:0.005040:0.010880:0.011208:0.010079:0.005604:0.010079:0.006713:0.008950:0.005040:0.010874:0.011208:0.005604:0.010079:0.010079:0.005604:0.008950:0.007842:0.005040:0.010876:0.008950:0.010079:0.010079:0.005040:0.010876:0.013446:0.005604:0.007842:0.010079:0.007842:0.005040:0.010882:0.017921:0.008950:0.010079:0.008950:0.010079:0.008950:0.015683:0.008950:0.010079:0.005604:0.006713:0.005040
National  Committee  of  Drugs,  Academy :@0.104762:0.486896:0.493144:0.486896:0.493144:0.467697:0.104762:0.467697:0.014555:0.008950:0.005604:0.005604:0.010079:0.010079:0.008950:0.005604:0.005040:0.014224:0.013446:0.010079:0.015683:0.015683:0.005604:0.005604:0.005604:0.008950:0.008950:0.005040:0.014212:0.010079:0.006713:0.005040:0.014236:0.014555:0.006713:0.010079:0.010079:0.007842:0.005040:0.005040:0.013131:0.014555:0.008950:0.008950:0.010079:0.008950:0.015683:0.010079:0.005040
of  Scientific  Research,  Ministry  of  Higher :@0.104762:0.504001:0.493136:0.504001:0.493136:0.484801:0.104762:0.484801:0.010079:0.006713:0.005040:0.008874:0.011208:0.008950:0.005604:0.008950:0.010079:0.005604:0.005604:0.005604:0.005604:0.008950:0.005040:0.008860:0.013446:0.008950:0.007842:0.008950:0.008950:0.006713:0.008950:0.010079:0.005040:0.005040:0.008864:0.017921:0.005604:0.010079:0.005604:0.006572:0.006572:0.006713:0.010079:0.005040:0.008874:0.010079:0.006713:0.005040:0.008874:0.014555:0.005604:0.010079:0.010079:0.008950:0.006713:0.005040
Education,  Elsayeda  Zeinab,  Egypt.:@0.104762:0.521105:0.438937:0.521105:0.438937:0.501905:0.104762:0.501905:0.012317:0.010079:0.010079:0.008950:0.008950:0.005604:0.005604:0.010079:0.010079:0.005040:0.005040:0.015091:0.012317:0.005604:0.007842:0.008950:0.010079:0.008950:0.010079:0.008950:0.005040:0.015095:0.012317:0.008950:0.005604:0.010079:0.008950:0.010079:0.005040:0.005040:0.015095:0.012317:0.010079:0.010079:0.010079:0.005604:0.005040
Abstract:@0.104762:0.544944:0.174027:0.544944:0.174027:0.525858:0.104762:0.525858:0.013446:0.010079:0.006632:0.006632:0.007842:0.010079:0.008950:0.005604
Concanavalin A (ConA) is an established model  Besides,  Con  A  was  correlated  to  high :@0.104762:0.568782:0.900280:0.567491:0.900280:0.548292:0.104762:0.549582:0.013446:0.010079:0.010079:0.008950:0.008950:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.010079:0.003276:0.013446:0.004407:0.006713:0.013446:0.010079:0.010079:0.014555:0.006713:0.004411:0.005604:0.007842:0.004407:0.008950:0.010079:0.004403:0.008950:0.006572:0.006572:0.008950:0.010079:0.005604:0.005604:0.007842:0.010079:0.008950:0.010079:0.004401:0.015683:0.010079:0.010079:0.008950:0.005604:0.005040:0.018761:0.013446:0.008950:0.007842:0.005604:0.010079:0.008950:0.007842:0.005040:0.005040:0.012658:0.013446:0.010079:0.010079:0.005040:0.011547:0.013446:0.005040:0.012660:0.014555:0.008950:0.007842:0.005040:0.012666:0.008950:0.010079:0.006713:0.006713:0.008950:0.005604:0.008950:0.005604:0.008950:0.010079:0.005040:0.012642:0.005604:0.010079:0.005040:0.012656:0.010079:0.005604:0.010079:0.010079:-0.256396
for  inducing  autoimmune  hepatitis  (AIH)  in  expression of cyclooxygenase COX-2 and this :@0.104762:0.585886:0.900280:0.584596:0.900280:0.565396:0.104762:0.566687:0.006713:0.010079:0.006713:0.005040:0.006015:0.005604:0.010079:0.010079:0.010079:0.008950:0.005604:0.010079:0.010079:0.005040:0.006009:0.008950:0.010079:0.005604:0.010079:0.005604:0.015683:0.015683:0.010079:0.010079:0.008950:0.005040:0.005993:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.005604:0.005604:0.007842:0.005040:0.005999:0.006713:0.014555:0.006713:0.014555:0.006713:0.005040:0.006021:0.005604:0.010079:0.005040:0.018763:0.008950:0.010079:0.010079:0.006713:0.008950:0.007842:0.007842:0.005604:0.010079:0.010079:0.006798:0.010079:0.006713:0.006800:0.008950:0.010079:0.008950:0.005604:0.010079:0.010079:0.010079:0.010079:0.010079:0.008950:0.010079:0.008950:0.007842:0.008950:0.006785:0.013446:0.014555:0.014555:0.006713:0.010079:0.006808:0.008950:0.010079:0.010079:0.006796:0.005604:0.010079:0.005604:0.007842:-0.280586
mice,  mimicking  clinical  features  in  human.  increasing  was  improved  by  administration :@0.104762:0.602991:0.900288:0.601700:0.900288:0.582500:0.104762:0.583791:0.015683:0.005604:0.008950:0.008950:0.005040:0.005040:0.005562:0.015683:0.005604:0.015683:0.005604:0.008950:0.010061:0.005604:0.010079:0.010079:0.005040:0.005570:0.008950:0.005604:0.005604:0.010079:0.005604:0.008950:0.008950:0.005604:0.005040:0.005552:0.006713:0.008950:0.008950:0.005604:0.010079:0.006713:0.008950:0.007842:0.005040:0.005566:0.005604:0.010079:0.005040:0.005570:0.010079:0.010079:0.015683:0.008950:0.010079:0.005040:0.005040:0.018763:0.005604:0.010079:0.008950:0.006713:0.008950:0.008950:0.007842:0.005604:0.010079:0.010079:0.005040:0.008840:0.014555:0.008950:0.007842:0.005040:0.008852:0.005604:0.015683:0.010079:0.006713:0.010079:0.010079:0.008950:0.010069:0.005040:0.008852:0.010079:0.010079:0.005040:0.008852:0.008950:0.010079:0.015683:0.005604:0.010079:0.005604:0.006572:0.006572:0.006713:0.008950:0.005604:0.005604:0.010079:0.010079:-0.304785
The  aim  of  the  current  study  is  to  explore  of  celecoxib.  These  changes  were  in  good :@0.104762:0.620095:0.900278:0.618804:0.900278:0.599605:0.104762:0.600895:0.012317:0.010079:0.008950:0.005040:0.006241:0.008950:0.005604:0.015683:0.005040:0.006239:0.010079:0.006713:0.005040:0.006249:0.005604:0.010079:0.008950:0.005040:0.006241:0.008950:0.010079:0.006713:0.006713:0.008950:0.010079:0.005604:0.005040:0.006239:0.006572:0.006572:0.010079:0.010079:0.010079:0.005040:0.006255:0.005604:0.007842:0.005040:0.006247:0.005604:0.010079:0.005040:0.006245:0.008950:0.010079:0.010079:0.005604:0.010079:0.006713:0.008950:0.005040:0.018761:0.010079:0.006713:0.005040:0.007697:0.008950:0.008950:0.005604:0.008950:0.008950:0.010079:0.010079:0.005604:0.010079:0.005040:0.005040:0.007314:0.012317:0.010079:0.008950:0.007842:0.008950:0.005040:0.007689:0.008950:0.010079:0.008950:0.010079:0.010079:0.008950:0.007842:0.005040:0.007691:0.014555:0.008950:0.006713:0.008950:0.005040:0.007693:0.005604:0.010079:0.005040:0.007695:0.010079:0.010079:0.010079:0.010079:-0.328965
the  possible  protective  effect  of  celecoxib,  a  agreement  with  improvement  in  histological :@0.104762:0.637199:0.900286:0.635909:0.900286:0.616709:0.104762:0.618000:0.005604:0.010079:0.008950:0.005040:0.004854:0.010079:0.010079:0.007842:0.007842:0.005604:0.010079:0.005604:0.008950:0.005040:0.004858:0.010079:0.006713:0.010079:0.005604:0.008950:0.008950:0.005604:0.005604:0.010079:0.008950:0.005040:0.004842:0.008950:0.006088:0.006088:0.008950:0.008950:0.005604:0.005040:0.004850:0.010079:0.006713:0.005040:0.004862:0.008950:0.008950:0.005604:0.008950:0.008950:0.010079:0.010079:0.005604:0.010079:0.005040:0.005040:0.004842:0.008950:0.005040:0.018765:0.008950:0.010079:0.006713:0.008950:0.008950:0.015683:0.008950:0.010079:0.005604:0.005040:0.006596:0.014555:0.005604:0.005604:0.010079:0.005040:0.006608:0.005604:0.015683:0.010079:0.006713:0.010079:0.010079:0.008950:0.015671:0.008950:0.010079:0.005604:0.005040:0.006608:0.005604:0.010079:0.005040:0.006612:0.010079:0.005604:0.006572:0.006572:0.010079:0.005604:0.010079:0.010079:0.005604:0.008950:0.008950:0.005604:-0.353164
cyclooxygenase-2 inhibitor, on immunological  deterioration. The protective effect of celecoxib :@0.104762:0.654304:0.900296:0.653013:0.900296:0.633813:0.104762:0.635104:0.008950:0.010079:0.008950:0.005604:0.010079:0.010079:0.010079:0.010079:0.010079:0.008950:0.010079:0.008950:0.007842:0.008950:0.006713:0.010079:0.007293:0.005604:0.010079:0.010079:0.005604:0.010079:0.005604:0.005604:0.010065:0.005904:0.005040:0.007308:0.010079:0.010079:0.007310:0.005604:0.015683:0.015683:0.010079:0.010079:0.010079:0.005604:0.010079:0.010079:0.005604:0.008950:0.008950:0.005604:0.005040:0.018743:0.010079:0.008950:0.005604:0.008950:0.006713:0.005604:0.010079:0.006713:0.008950:0.005604:0.005604:0.010079:0.010079:0.005040:0.004632:0.012317:0.010079:0.008950:0.005011:0.010079:0.006713:0.010079:0.005604:0.008950:0.008950:0.005604:0.005604:0.010079:0.008950:0.004999:0.008950:0.006088:0.006088:0.008950:0.008950:0.005604:0.005005:0.010079:0.006713:0.005020:0.008950:0.008950:0.005604:0.008950:0.008950:0.010079:0.010079:0.005604:0.010079:-0.377364
responses elicited in the ConA model of acute  was  also  associated  with  significant  reduction :@0.104762:0.671408:0.900290:0.670117:0.900290:0.650918:0.104762:0.652208:0.006713:0.008950:0.007842:0.010079:0.010079:0.010079:0.007842:0.008950:0.007842:0.006943:0.008950:0.005604:0.005604:0.008950:0.005604:0.005604:0.008950:0.010079:0.006914:0.005604:0.010079:0.006937:0.005604:0.010079:0.008950:0.006931:0.013446:0.010079:0.010079:0.013446:0.006939:0.015683:0.010079:0.010079:0.008950:0.005604:0.006929:0.010079:0.006713:0.006939:0.008950:0.008950:0.010079:0.005604:0.008950:0.005040:0.018757:0.014555:0.008950:0.007842:0.005040:0.003106:0.008950:0.005604:0.007842:0.010079:0.005040:0.003100:0.008950:0.007842:0.007842:0.010079:0.008950:0.005604:0.008950:0.005604:0.008950:0.010079:0.005040:0.003090:0.014555:0.005604:0.005604:0.010079:0.005040:0.003100:0.007842:0.005604:0.010079:0.010079:0.005604:0.005604:0.005604:0.008950:0.008950:0.010079:0.005604:0.005040:0.003092:0.006713:0.008950:0.010079:0.010079:0.008950:0.005604:0.005604:0.010079:0.010079:-0.401549
hepatitis.  ConA  (20  mg/kg)  was  administered  of autophagy biomarkers (Beclin-1 and LC3II). :@0.104762:0.688513:0.900286:0.687222:0.900286:0.668022:0.104762:0.669313:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.005604:0.005604:0.007842:0.005040:0.005040:0.003477:0.013446:0.010079:0.010079:0.013444:0.005040:0.003494:0.006713:0.010079:0.010079:0.005040:0.003494:0.015683:0.010079:0.005604:0.010079:0.010079:0.006713:0.005040:0.003485:0.014555:0.008950:0.007842:0.005040:0.003498:0.008950:0.010079:0.015683:0.005604:0.010079:0.005604:0.006572:0.006572:0.008950:0.006713:0.008950:0.010079:0.005040:0.018757:0.010079:0.006713:0.005126:0.008950:0.010079:0.005604:0.010079:0.010079:0.010079:0.008950:0.010079:0.010079:0.005124:0.010079:0.005604:0.010079:0.015683:0.008950:0.006713:0.010079:0.008950:0.006713:0.007842:0.005116:0.006713:0.013446:0.008950:0.008950:0.005604:0.005604:0.010079:0.006713:0.010079:0.005114:0.008950:0.010079:0.010079:0.005124:0.012317:0.013446:0.010079:0.006713:0.006713:0.006713:0.005040:-0.425735
intravenously to adult male mice for 6 h. Prior  In  conclusion,  celecoxib  showed  antioxidant, :@0.104762:0.705617:0.900304:0.704326:0.900304:0.685127:0.104762:0.686417:0.005604:0.010079:0.005604:0.006713:0.008950:0.010079:0.008950:0.010079:0.010079:0.010079:0.007842:0.005604:0.010079:0.006267:0.005604:0.010079:0.006277:0.008950:0.010079:0.010079:0.005604:0.005604:0.006269:0.015683:0.008950:0.005604:0.008938:0.006279:0.015683:0.005604:0.008950:0.008950:0.006267:0.006713:0.010079:0.006713:0.006281:0.010079:0.006279:0.010079:0.005040:0.006281:0.011208:0.006713:0.005604:0.010079:0.006713:0.005040:0.018769:0.006713:0.010079:0.005040:0.004862:0.008950:0.010079:0.010079:0.008950:0.005604:0.010079:0.007842:0.005604:0.010079:0.010079:0.005040:0.005040:0.004862:0.008950:0.008950:0.005604:0.008950:0.008950:0.010079:0.010079:0.005604:0.010079:0.005040:0.004844:0.007842:0.010079:0.010079:0.014555:0.008950:0.010079:0.005040:0.004866:0.008950:0.010079:0.005604:0.005604:0.010079:0.010079:0.005604:0.010079:0.008950:0.010079:0.005604:0.005040:-0.449944
to ConA intoxication, mice in the treated groups  anti-inflammatory,  anti-apoptotic  and  anti-:@0.104762:0.722721:0.895247:0.721431:0.895247:0.702231:0.104762:0.703522:0.005604:0.010079:0.004292:0.013446:0.010079:0.010079:0.013446:0.004298:0.005604:0.010079:0.005604:0.010079:0.010079:0.005604:0.008950:0.008950:0.005604:0.005604:0.010079:0.010079:0.005040:0.004280:0.015683:0.005604:0.008950:0.008938:0.004296:0.005604:0.010079:0.004292:0.005604:0.010079:0.008950:0.004292:0.005604:0.006713:0.008950:0.008950:0.005604:0.008950:0.010079:0.004280:0.010079:0.006713:0.010079:0.010079:0.010079:0.007842:0.005040:0.018765:0.008950:0.010079:0.005604:0.005604:0.006713:0.005604:0.010079:0.005604:0.005604:0.008950:0.015683:0.015683:0.008950:0.005604:0.010079:0.006713:0.008745:0.005040:0.005040:0.013639:0.008950:0.010079:0.005604:0.005604:0.006713:0.008950:0.010067:0.010079:0.010079:0.005604:0.010079:0.005604:0.005604:0.008950:0.005040:0.013627:0.008950:0.010079:0.010079:0.005040:0.013635:0.008950:0.010079:0.005604:0.005604:-0.467403
received  daily  doses  of  celecoxib  (30  and  60  autophagy  activity  against  Con  A-induced :@0.104762:0.739826:0.900282:0.738535:0.900282:0.719335:0.104762:0.720626:0.006713:0.008950:0.008950:0.008950:0.005604:0.010079:0.008950:0.010079:0.005040:0.003489:0.010079:0.008950:0.005604:0.005604:0.010069:0.005040:0.003504:0.010079:0.010079:0.007842:0.008950:0.007842:0.005040:0.003510:0.010079:0.006713:0.005040:0.003504:0.008950:0.008950:0.005604:0.008950:0.008950:0.010079:0.010079:0.005604:0.010079:0.005040:0.003491:0.006713:0.010079:0.010079:0.005040:0.003506:0.008950:0.010079:0.010079:0.005040:0.003502:0.010079:0.010079:0.005040:0.018763:0.008950:0.010079:0.005604:0.010079:0.010079:0.010079:0.008950:0.010079:0.010079:0.005040:0.011081:0.008950:0.008950:0.005604:0.005604:0.010079:0.005604:0.005604:0.010079:0.005040:0.011073:0.008950:0.010079:0.008950:0.005604:0.010079:0.006572:0.006572:0.005040:0.011087:0.013446:0.010079:0.010079:0.005040:0.009979:0.014555:0.006713:0.005604:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:-0.498303
mg/kg  in  CMC)  for  7  days.  Results  revealed  immune-mediated  hepatitis.  These  effects :@0.104762:0.756930:0.900286:0.755639:0.900286:0.736440:0.104762:0.737730:0.015683:0.010079:0.005604:0.010079:0.010079:0.005040:0.003725:0.005604:0.010079:0.005040:0.003729:0.013446:0.017921:0.013446:0.006713:0.005040:0.003733:0.006713:0.010079:0.006713:0.005040:0.003733:0.010079:0.005040:0.003731:0.010079:0.008950:0.010079:0.007842:0.005040:0.005040:0.003733:0.013446:0.008950:0.007842:0.010079:0.005604:0.005604:0.007842:0.005040:0.003727:0.006713:0.008950:0.010079:0.008950:0.008950:0.005604:0.008950:0.010079:0.005040:0.018757:0.005604:0.015683:0.015683:0.010079:0.010079:0.008950:0.006713:0.015683:0.008950:0.010079:0.005604:0.008950:0.005604:0.008950:0.010079:0.005040:0.015960:0.010079:0.008950:0.010079:0.008950:0.005604:0.005592:0.005604:0.005604:0.007842:0.005040:0.005040:0.015625:0.012317:0.010079:0.008950:0.007842:0.008950:0.005040:0.015986:0.008950:0.006088:0.006088:0.008950:0.008950:0.005604:0.007842:-0.522497
that administration of celecoxib 60 mg/kg for  could be produced by modulation of Nrf2/HO-:@0.104762:0.774034:0.895232:0.772744:0.895232:0.753544:0.104762:0.754835:0.005604:0.010079:0.008950:0.005604:0.007947:0.008950:0.010079:0.015683:0.005604:0.010079:0.005604:0.006572:0.006572:0.006713:0.008950:0.005604:0.005604:0.010079:0.010079:0.007947:0.010079:0.006713:0.007959:0.008950:0.008950:0.005604:0.008936:0.008950:0.010079:0.010079:0.005604:0.010079:0.007951:0.010079:0.010079:0.007959:0.015683:0.010079:0.005604:0.010079:0.010079:0.007949:0.006713:0.010079:0.006713:0.005040:0.018765:0.008950:0.010079:0.010079:0.005604:0.010079:0.006034:0.010079:0.008950:0.006038:0.010079:0.006713:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:0.006034:0.010079:0.010079:0.006042:0.015683:0.010079:0.010079:0.010079:0.005604:0.008950:0.005604:0.005604:0.010079:0.010079:0.006027:0.010079:0.006713:0.006042:0.014555:0.006713:0.006713:0.010079:0.005604:0.014555:0.014555:-0.539961
7  days  significantly  protected  the  liver  from  1,  IL-1B  /p-JNK/p-AKT,  JNK/caspase-3,  and :@0.104762:0.791139:0.900280:0.789848:0.900280:0.770648:0.104762:0.771939:0.010079:0.005040:0.005108:0.010079:0.008950:0.010079:0.007842:0.005040:0.005106:0.007842:0.005604:0.010079:0.010079:0.005604:0.005604:0.005604:0.008950:0.008950:0.010079:0.005604:0.005604:0.010079:0.005040:0.005094:0.010079:0.006713:0.010079:0.005604:0.008950:0.008950:0.005604:0.008950:0.010079:0.005040:0.005098:0.005604:0.010079:0.008950:0.005040:0.005100:0.005604:0.005604:0.010079:0.008950:0.006713:0.005040:0.005098:0.006713:0.006713:0.010079:0.015683:0.005040:0.018761:0.010079:0.005040:0.005040:0.004253:0.006713:0.012317:0.006713:0.010079:0.013446:0.005040:0.004249:0.005604:0.010079:0.006713:0.007842:0.014555:0.014555:0.005604:0.010079:0.006713:0.014555:0.014555:0.010827:0.005040:0.005040:0.004253:0.007842:0.014555:0.014555:0.005604:0.008950:0.008950:0.007842:0.010079:0.008950:0.007842:0.008950:0.006713:0.010079:0.005040:0.005040:0.004253:0.008950:0.010079:0.010079:-0.570872
ConA-induced  liver  damage  revealed  by  Beclin-1/LC3II signaling pathways. :@0.104762:0.808243:0.807754:0.806952:0.807754:0.787753:0.104762:0.789043:0.013446:0.010079:0.010079:0.014555:0.006713:0.005604:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:0.005040:0.014105:0.005604:0.005604:0.010079:0.008950:0.006713:0.005040:0.014101:0.010079:0.008950:0.015683:0.008950:0.010079:0.008950:0.005040:0.014103:0.006713:0.008950:0.010079:0.008950:0.008950:0.005604:0.008950:0.010079:0.005040:0.014095:0.010079:0.010079:0.005040:0.018765:0.013446:0.008950:0.008950:0.005604:0.005604:0.010079:0.006713:0.010079:0.005604:0.012317:0.013446:0.010079:0.006713:0.006713:0.005701:0.007842:0.005604:0.010079:0.010079:0.008950:0.005604:0.005604:0.010079:0.010079:0.005709:0.010079:0.008950:0.005604:0.010079:0.014555:0.008950:0.010079:0.007842:0.005040:-0.502536
significant  decrease  in  ALT  and  AST  serum :@0.104762:0.825347:0.493142:0.825347:0.493142:0.806148:0.104762:0.806148:0.007842:0.005604:0.010079:0.010079:0.005604:0.005604:0.005604:0.008950:0.008950:0.010079:0.005604:0.005040:0.005526:0.010079:0.008950:0.008950:0.006713:0.008950:0.008950:0.007842:0.008950:0.005040:0.005528:0.005604:0.010079:0.005040:0.004421:0.014555:0.010466:0.011948:0.005040:0.005536:0.008950:0.010079:0.010079:0.005040:0.004421:0.014555:0.011208:0.011956:0.005040:0.005536:0.007842:0.008950:0.006713:0.010079:0.015683:0.005040
levels. Celecoxib 30 and 60 mg/kg pretreatment :@0.104762:0.842452:0.493160:0.842452:0.493160:0.823252:0.104762:0.823252:0.005604:0.008950:0.010079:0.008950:0.005604:0.007842:0.005040:0.004449:0.013446:0.008950:0.005604:0.008950:0.008950:0.010065:0.010079:0.005604:0.010079:0.004455:0.010079:0.010079:0.004457:0.008950:0.010079:0.010079:0.004455:0.010079:0.010079:0.004457:0.015683:0.010079:0.005604:0.010079:0.010079:0.004451:0.010079:0.006713:0.008950:0.005604:0.006713:0.008950:0.008950:0.005604:0.015683:0.008950:0.010079:0.005604:0.005040
enhanced  oxidant/antioxidant  hemostasis  by :@0.104762:0.859556:0.493136:0.859556:0.493136:0.840357:0.104762:0.840357:0.008950:0.010079:0.010079:0.008950:0.010079:0.008950:0.008950:0.010079:0.005040:0.008993:0.010079:0.010079:0.005604:0.010079:0.008950:0.010079:0.005604:0.005604:0.008950:0.010079:0.005604:0.005604:0.010079:0.010079:0.005604:0.010051:0.008950:0.010079:0.005604:0.005040:0.008999:0.010079:0.008950:0.015683:0.010079:0.006572:0.006572:0.008950:0.007842:0.005604:0.007842:0.005040:0.009005:0.010079:0.010079:0.005040
significant reduction of MDA and NO content :@0.104762:0.876661:0.493148:0.876661:0.493148:0.857461:0.104762:0.857461:0.007842:0.005604:0.010079:0.010079:0.005604:0.005604:0.005604:0.008950:0.008950:0.010079:0.005604:0.007146:0.006713:0.008950:0.010079:0.010079:0.008950:0.005604:0.005604:0.010079:0.010079:0.007146:0.010079:0.006713:0.007156:0.017921:0.014555:0.013450:0.007156:0.008950:0.010079:0.010079:0.007152:0.014555:0.014555:0.007164:0.008950:0.010079:0.010079:0.005604:0.008950:0.010079:0.005604:0.005040
and  increase  hepatic  GSH  contents  and  SOD :@0.104762:0.893765:0.493122:0.893765:0.493122:0.874565:0.104762:0.874565:0.008950:0.010079:0.010079:0.005040:0.003800:0.005604:0.010079:0.008950:0.006713:0.008950:0.008950:0.007842:0.008950:0.005040:0.003798:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.008950:0.005040:0.003786:0.014555:0.011208:0.014555:0.005040:0.003804:0.008950:0.010079:0.010079:0.005604:0.008950:0.010079:0.005604:0.007842:0.005040:0.003794:0.008950:0.010079:0.010079:0.005040:0.003800:0.011208:0.014555:0.014555:0.005040
activity. In addition, celecoxib 30 and 60 mg/:@0.104762:0.910869:0.488102:0.910869:0.488102:0.891670:0.104762:0.891670:0.008950:0.008950:0.005604:0.005604:0.010079:0.005604:0.005604:0.008751:0.005040:0.007604:0.006713:0.010079:0.007606:0.008950:0.010079:0.010079:0.005604:0.005604:0.005604:0.010079:0.010079:0.005040:0.007592:0.008950:0.008950:0.005604:0.008950:0.008950:0.010079:0.010079:0.005604:0.010079:0.007586:0.010079:0.010079:0.007604:0.008950:0.010079:0.010079:0.007602:0.010079:0.010079:0.007606:0.015683:0.010079:0.005604
kg caused significant increase in hepatic nuclear :@0.104762:0.927974:0.493152:0.927974:0.493152:0.908774:0.104762:0.908774:0.010079:0.010079:0.004185:0.008950:0.008950:0.010079:0.007842:0.008950:0.010079:0.004183:0.007842:0.005604:0.010079:0.010079:0.005604:0.005604:0.005604:0.008950:0.008950:0.010079:0.005604:0.004177:0.005604:0.010079:0.008950:0.006713:0.008950:0.008938:0.007842:0.008950:0.004185:0.005604:0.010079:0.004181:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.008950:0.004171:0.010079:0.010079:0.008950:0.005604:0.008950:0.008950:0.006713:0.005040
factor  erythroid  2-related  factor  2  (Nrf2)  and :@0.511904:0.447761:0.900286:0.447761:0.900286:0.428561:0.511904:0.428561:0.006713:0.008950:0.008950:0.005604:0.010079:0.006713:0.005040:0.003806:0.008950:0.006713:0.010079:0.005604:0.010079:0.006713:0.010079:0.005604:0.010079:0.005040:0.003814:0.010079:0.006713:0.006713:0.008950:0.005604:0.008950:0.005604:0.008950:0.010079:0.005040:0.003800:0.006713:0.008950:0.008950:0.005604:0.010079:0.006713:0.005040:0.003808:0.010079:0.005040:0.003816:0.006713:0.014555:0.006713:0.006713:0.010079:0.006713:0.005040:0.003820:0.008950:0.010079:0.010079:0.005040
the  stress  protein  heme  oxygenase-1  (HO-1) :@0.511904:0.464865:0.900270:0.464865:0.900270:0.445665:0.511904:0.445665:0.005604:0.010079:0.008950:0.005040:0.005403:0.006572:0.006572:0.006713:0.008950:0.007842:0.007842:0.005040:0.005419:0.010079:0.006713:0.010079:0.005604:0.008950:0.005604:0.010079:0.005040:0.005399:0.010079:0.008950:0.015683:0.008950:0.005040:0.005399:0.010079:0.010079:0.010079:0.010079:0.008950:0.010079:0.008950:0.007842:0.008950:0.006713:0.010079:0.005040:0.005403:0.006713:0.014555:0.014555:0.006713:0.010079:0.006713:0.005040
levels.  Moreover,  celecoxib  30  and  60  mg/:@0.511904:0.481969:0.895245:0.481969:0.895245:0.462770:0.511904:0.462770:0.005604:0.008950:0.010079:0.008950:0.005604:0.007842:0.005040:0.005040:0.006542:0.017921:0.010079:0.006713:0.008950:0.010079:0.010079:0.008950:0.005902:0.005040:0.005040:0.006552:0.008950:0.008950:0.005604:0.008950:0.008950:0.010079:0.010063:0.005604:0.010079:0.005040:0.006548:0.010079:0.010079:0.005040:0.006552:0.008950:0.010079:0.010079:0.005040:0.006548:0.010079:0.010079:0.005040:0.006552:0.015683:0.010079:0.005604
kg  inhibited  the  release  of  proinflammatory :@0.511904:0.499074:0.900294:0.499074:0.900294:0.479874:0.511904:0.479874:0.010079:0.010079:0.005040:0.006691:0.005604:0.010079:0.010079:0.005604:0.010079:0.005604:0.005604:0.008950:0.010079:0.005040:0.006673:0.005604:0.010079:0.008950:0.005040:0.006683:0.006713:0.008950:0.005604:0.008950:0.008950:0.007842:0.008950:0.005040:0.006679:0.010079:0.006713:0.005040:0.006691:0.010079:0.006713:0.010079:0.005604:0.010079:0.005604:0.005604:0.008950:0.015683:0.015683:0.008950:0.005604:0.010079:0.006713:0.010079:0.005040
markers  including  IL-1β  and  TNF-α  along :@0.511904:0.516178:0.900284:0.516178:0.900284:0.496978:0.511904:0.496978:0.015683:0.008950:0.006713:0.010079:0.008950:0.006713:0.007842:0.005040:0.008414:0.005604:0.010079:0.008950:0.005604:0.010079:0.010079:0.005604:0.010079:0.010079:0.005040:0.008406:0.006713:0.012317:0.006713:0.010079:0.010261:0.005040:0.008414:0.008950:0.010079:0.010079:0.005040:0.008053:0.012317:0.014555:0.011208:0.006713:0.010563:0.005040:0.008422:0.008950:0.005604:0.010079:0.010079:0.010079:0.005040
with  significant  decrease  in  p-JNK,  AKT :@0.511904:0.533282:0.900272:0.533282:0.900272:0.514083:0.511904:0.514083:0.014555:0.005604:0.005604:0.010079:0.005040:0.010825:0.007842:0.005604:0.010079:0.010079:0.005604:0.005604:0.005604:0.008950:0.008950:0.010079:0.005604:0.005040:0.010815:0.010079:0.008950:0.008950:0.006713:0.008950:0.008950:0.007842:0.008950:0.005040:0.010815:0.005604:0.010079:0.005040:0.010825:0.010079:0.006713:0.007842:0.014555:0.014555:0.005040:0.005040:0.009727:0.014555:0.014555:0.012317:0.005040
phosphorylation ratio and caspase-3 expression. :@0.511904:0.550387:0.900280:0.550387:0.900280:0.531187:0.511904:0.531187:0.010079:0.010079:0.010079:0.007842:0.010079:0.010079:0.010079:0.006713:0.010079:0.005604:0.008950:0.005604:0.005604:0.010079:0.010079:0.004155:0.006713:0.008950:0.005604:0.005604:0.010079:0.004155:0.008950:0.010079:0.010079:0.004161:0.008950:0.008950:0.007842:0.010079:0.008950:0.007842:0.008950:0.006713:0.010079:0.004159:0.008950:0.010079:0.010079:0.006713:0.008950:0.007842:0.007842:0.005604:0.010079:0.010079:0.005040:0.005040
https://doi.:@0.808431:0.806952:0.895255:0.806952:0.895255:0.787753:0.808431:0.787753:0.010079:0.005604:0.005604:0.010079:0.007842:0.005604:0.005604:0.005604:0.010079:0.010079:0.005604:0.005040
org/10.1016/j.intimp.2023.110442:@0.511904:0.824057:0.807320:0.824057:0.807320:0.804857:0.511904:0.804857:0.010684:0.006961:0.010684:0.006209:0.010684:0.010684:0.005644:0.010684:0.010684:0.010684:0.010684:0.006209:0.006209:0.005644:0.006209:0.010684:0.006209:0.006209:0.016288:0.010684:0.005644:0.010684:0.010684:0.010684:0.010684:0.005644:0.009942:0.010684:0.010684:0.010684:0.010684:0.010079